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From protein binding to pharmaokinetis: a novel approah to ative drug
absorption predition.
P.O. Fedihev, T.V. Kolesnikova, and A.A. Vinnik
Quantum Pharmaeutials, Ul. Kosmonavta Volkova 6-606, 125171, Mosow, Russia
Due to inherent omplexity ative transport presents a landmark hurdle for oral absorption prop-
erties predition. We present a novel approah arrier-mediated drug absorption parameters al-
ulation based on entirely dierent paradigm than QSPR. We apitalize on reently emerged ideas
that moleule ativities against a large protein set an be used for predition of biologial eets
and performed a large sale numerial doking of drug-like ompounds to a large diversied set of
proteins. As a result we identied for the rst time a protein, binding to whih orrelates well with
the intestinal permeability of many atively absorbed ompounds. Although the protein is not a
transporter, we speulate that it has the binding site fore eld similar to that of an important in-
testinal transporter. The observation helped us to improve the passive absorption model by adding
non-liner ux assoiated with the transporting protein to obtain a quantitative model of ative
transport. This study demonstrates that binding data to a suiently representative set of proteins
an serve as a basis for ative absorption predition for a given ompound.
I. INTRODUCTION
The oral route of drug administration is very onve-
nient for patients, however it is often ineient due to
low solubility, intestinal permeability, or high rst-pass
eet. Therefore predition of oral absorption properties
is of great interest for pharmaeutial industry. Orally
administered drugs are mainly absorbed in the small in-
testine. Here, depending on drug omposition and size,
absorption an happen through a variety of proesses
[35℄. Drug pass through the epithelial ells and the lam-
ina propria from the lumen into the blood stream in the
apillaries. On its way it might be metabolized, trans-
ported away from the trat where absorption is possible
or aumulate in organs other than those of treatment.
Besides a fundamental interest in understanding the ba-
si mehanisms by whih a drug is assimilated by the hu-
man body, the kinetis of drug absorption is also a topi
of muh pratial interest. A detailed knowledge of this
proess, resulting in the predition of the drug absorp-
tion prole, an be of muh help in the drug development
stage [19℄.
There are a number of kineti absorption models were
developed that require experimentally determined in-
testinal permeability of a ompound as an input [74℄.
Although of great value suh hybrid partially exper-
imental, partially omputational models miss the main
advantages of purely theoretial approahes: no need in
hemial synthesis of a ompound and experimental fail-
ities, low ost and high speed. Among omputational ap-
proahes that predit intestinal permeability solely from
a moleule struture and its physial-hemial proper-
ties instead of using any biologial experiments data,
there are two major diretions: ab initio and quantitative
struture-property relationship (QSPR) models. The last
ones are overwhelmingly used nowadays and exploit a
wide spetrum of statistial methods for absorption data
analysis (see e.g. [12, 33, 61℄ for a review). Instead of
relying on basi laws of nature the models are trained at
observed statistial regularities. Suh an approah pre-
onditions the limitations of the models. In ontrast to
QSPR there are a handful of studies developing mod-
els of the intestinal permeability from the rst priniples
[2, 14, 50℄. The models desribe suessfully basi prop-
erties of passive absorption: dependene on distribution
oeient, diusional limitation at high LogD, and para-
ellular absorption. However, the major hindrane on
this way the omplexity of intestinal absorption. Apart
from passive phenomena (diusion through ell mem-
brane and paraellular juntions), there is also ative
transport of the moleules in and out of the ells. To the
best of our knowledge urrent ab initio models are limited
to desription of drug passive absorption. Most of QSPR
models also deal with passive transport [12℄, though only
a few approahes go as far as developing QSPR models
desribing both passive and arrier-mediated absorption
mehanisms [67℄. However, arrier-mediated transport
plays an important role in drug absorption [18℄ and hene
demands the development of a good ative absorption
model.
The major objetive of this investigation was to de-
velop a novel approah to predition of arrier-mediated
drug absorption based on entirely dierent paradigm
than QSPR, thus avoiding its diulties and apable of
better preditions. Reently it was observed that experi-
mental values of moleular ativities against a large pro-
tein set an be used for predition of a broad spetrum
of biologial eets . In this study we took advantage of
this onept and developed a novel quantitative method
for identiation of atively transported drugs. To do
that we performed a doking study of a few hundreds
of small moleules (mostly drugs) against a diversied
set of 400 proteins representing human proteom. Using
available absorption data for eah of the moleules we
identied a protein, anity for whih orrelates well with
the permeability of many atively absorbed ompounds
from our data set. The observation helped us to improve
the passive absorption model by adding non-liner uxes
2assoiated with the transporting protein to obtain also a
quantitative model of ative transport.
The manusript is organized as follows. After the
standard Materials and Methods setion outlining our
approahes to the data preparation, the doking study
setup, and the data proessing routines, we present a
two-ompartment model of drug absorption extended to
inlude ative transport via non-linear uxes terms asso-
iated with transporting proteins. As soon as the model
is built and the parameters of passive absorption are t-
ted to experimental data, we identify the ative transport
parameters to train the lassier. After the lassiation
is set up we ompare our preditions with available ex-
perimental informaton and thus validate the omplete
model for drug absorption predition.
II. MATERIALS AND METHODS
A. Experimental absorption and permeability data
Muh experimental ativity aimed to analyze the ki-
neti aspets of the proess of drug absorption has been
pursued reently. For better ontrol, a variety of in-
vitro methods on drug absorption have been developed
[9℄. One possibility is to seed (epithelial) ell ultures
in a mono-layer, forming the ontat surfae of two little
pots. Conentrations of an applied drug an be measured
over time in both hambers. Two well known ell ulture
models are Cao-2 ells [6, 8℄ and MDCK ells [37℄.
To enrih experimental data sets we used two types of
observed data to build up the model: fration of drugs
absorbed after oral administration in humans (FA) and
permeability aross a human olon adenoarinoma ell
(Cao-2) monolayer (P ). The latter is a routinely used
ell model in pharmaeutial industry and aademia to
estimate drug absorption in the intestine [8, 10, 36, 65℄).
Previous ndings showed strong relationship between
drug Cao-2 permeability and the fration absorbed in
humans (e.g. [7, 10, 46, 60, 62, 73℄), suggesting that one
value an be used to estimate the other. We olleted
from literature ompilations 91 observed FA values and
103 Cao-2 permeability values for 117 ompounds that
to the best of our knowledge are not subjet to eux
from enteroytes [4, 10, 11, 13, 15, 17, 20, 24, 28, 29, 30,
32, 34, 38, 39, 40, 42, 43, 45, 46, 49, 51, 53, 54, 55, 56, 57,
58, 60, 61, 62, 64, 67, 72, 73, 75℄. Fig. 1 shows FA val-
ues plotted against permeability for the ompounds, for
whih both values were available. The data were tted
with the sigmoid equation [8℄:
FA =
100%
1 + (P/P50)p
(1)
where P50 is the permeability at 50%FA, and p is a slope
fator. The tting parameters were P50 = 7.94 × 10
−7
cm · s−1 and p = −0.73 that is in reasonable agree-
ment with previously found P50 ∼ 2× 10
−6 cm · s−1 and
Figure 1: The relationship between FA and Cao-2 perme-
ability. The points orresponds to experimental values for
ompounds with both values of FA and P known. The solid
line is the approximation provided by Eq. 1. RMSD is 14%.
p = −0.5 [46℄. The tting urve predits FA = 90% for
logP90 = −4.8 and FA = 10% for logP10 = −7.4, whih
is in a reasonable agreement with with logP90 = −5.3
and logP10 = −6.9 from [60℄. RMSD of the tting is
fairly small and thus Cao-2 permeability an indeed pre-
dit human intestinal absorption of orally taken drugs
with reasonable auray. Fig. 1 shows that there are
two outliers orresponding to glyylsarosine and amox-
iillin. Their FA were muh higher than expeted from
Cao-2 permeability. Glyylsarosine and amoxiillin are
arried through enteroyte membranes by PEPT trans-
porters, whih are reported to have redued ativity in
Cao-2 ells [16, 41℄. This fat may aount for observed
disrepany between measured Cao-2 permeability and
FA values.
Eq. 1 an be used to estimate the missing values of
FA and P for all the ompounds from our ompilation.
However, Eq. 1 requires that if FA → 100%, then P →
∞. Therefore, if the observed value of FA exeeded 97%,
we assigned P value of 4 × 10−4 cm/s orresponding to
97% FA.
The distribution oeients, LogD (pH = 7.4) used
throughout the researh, were either olleted from liter-
ature [13, 47, 71℄ or alulated using Quantum software
version 3.3.0 [1℄.
B. Preparation of the protein panel
Our protein data set inludes 400 proteins form the
Protein Data Bank [68℄. It overs about almost all avail-
able ytoplasmi proteins with known X-ray struture
and also inludes some important transmembranal pro-
3teins suh as ion hannels and GPCRs. We use homology
models for GPCRs sine no experimentally determined
struture is available [59℄.
Only the proteins that are o-rystallized with biolog-
ially ative ligand were taken to the data set. Ligands
may be either natural ligands (suh as hormone for a
hormone reeptor or substrate for enzyme), or drugs, in-
hibitors et. If there exist multiple les in PDB reposi-
tory for the same protein, we onsider the le with the
most omplete struture and/or the lowest resolution.
Although the hoie of the proteins for the alula-
tions is a very important step and the overall number of
proteins is hardly manageable, we believe that the PDB
arhive ontains a representative set of the most prati-
ally important proteins, overing the whole interesting
variety of ligand binding domains. Below we show, that
suessful preditions do not require the presene of a
spei ligand binder in the protein set employed for the
alulations. Instead, it proves to be suient to have a
struturally similar protein in the protein panel.
C. Doking setup and the binding onstant, Kd,
predition.
Both the proteins and small moleules typization, and
in-silio sreening were arried out by the moleular pro-
essing and doking tools taken from the QUANTUM
drug disovery software suit [1℄. The software predits
the binding anities of small moleules to resolved pro-
tein targets using a set of rst priniples based moleular
simulations with an advaned ontinuous water model
[22, 23℄. The approah provides the logarithmi values of
the binding onstant, pKd (− lgKd).
To ompute the binding anities of moleules in our
data set we sreened eah of the moleules against every
protein in our panel. To speed up the alulations the
doking run were performed against rigid protein stru-
tures with no further renement by moleular dynamis.
Suh a simplied approah turned out to be suient (see
the disussion below) and the results of the alulations
were organized into sreening assays ontaining pKd val-
ues for eah protein-small moleules pair (omplexes) and
were stored for further analysis.
D. Data proessing and modeling.
Fitting of the experimental data to the models pro-
posed below was performed using BFGS algorithm im-
plemented in in-house program. Seletion of proteins,
anity for whih orrelates with ative absorption was
performed using Weka v.3.5 data mining software [70℄.
Figure 2: Model of absorption used in the study. The gures
represent: 1 and 5  drug diusion from the balk solution of
the donor tank to enteroytes and from enteroytes to the
balk solution of the aeptor tank; 2 and 3  passive and
ative penetration through ells; 4  drug diusion inside en-
teroyte from the apial to basal membrane of enteroytes;
4  paraellular absorption of the drug. The drug dissolving
stage in the intestinal lumen is omitted.
III. RESULTS
A. The model
For the sake of simpliity we onsidered absorption of
passively and atively transported drugs with negligible
eux and intestinal metabolism. Besides, the model as-
sumes that the drug is good soluble and stable in the gas-
trointestinal uids, and absorption on intestinal ontent
and intestinal metabolism are negligible. In this ase the
absorption from intestinum to blood an be represented
by a two-ompartment model (see Fig. 2) onsisting of a
donor (intestinal lumen) and an aeptor (blood vessel)
tanks. The intestinal wall an be represented by a single
lipid membrane sine there is no phenomena depending
on drug onentration in enteroytes. The drug absorp-
tion an be desribed as drug diusion from the balk
solution of the donor tank to the ell layer, penetration
aross it, and diusion away from the layer to the balk
solution of the aeptor tank in series. Drug penetration
aross lipid layer inludes passive diusion, ative trans-
port and diusion through pores in the layer simulating
paraellular absorption.
The eetive permeability oeient, P , through a
ombination of diusional barriers and ative transports
is determined by the following equation [27℄:
P−1 = P−1UWL + (Ppass + Pact + Ppara)
−1, (2)
4where Ppass, Pact, Pparaare the passive, ative, paraellu-
lar permeabilities. PUWL is the eetive permeability of
unstirred water layers (UWL) in the donor and aeptor
tanks:
P−1UWL = P
−1
UWL,1 + P
−1
UWL,2
The values of the permeabilities ome from the Fik's law
PUWL,i =
DUWL,i
hUWL,i
(3)
where DUWL,i and hUWL,i are the diusion oeient
and eetive thikness of UWL on eah side of the ell
monolayer. DUWL,i an be approximated by the diu-
sional oeient in water, whih varies within less than
a single order of magnitude for low moleular weight or-
gani ompounds [52, 69℄. For suiently dilute solutions
hUWL is approximately onstant. Thus, PUWL,i and ef-
fetive permeability of the UWLs, PUWL an be approx-
imately treated onstant for all low moleular weight or-
gani ompounds.
Similarly to PUWL,i, the drug diusion through mem-
brane, Ppass, an be estimated as:
Ppass =
DM
hM
D (4)
where DM is the diusion oeient in lipid, hM is the
thikness of the membrane, and D is the otanol/water
distribution oeient, i.e. the onentration ratio be-
tween aqueous and lipid phases. And again, as a rst
approximation DM an be put to a onstant for various
drug-like ompounds, thus the proportionality fator be-
tween Ppass and D an be onsidered as onstant for all
low moleular weight organi ompounds.
Aording to [2, 3℄, the paraellular permeability,
Ppara, is a size-restrited diusion within a negative ele-
trostati fore eld. Normally it varies within a single
order of magnitude range [2, 52℄ and hene its variations
an be negleted. In what follows we keep Ppara onstant
everywhere. The analysis of the experimental data at our
disposal proves that this is a very reasonable assumption
indeed.
To build up a model of ative transport rst we es-
timated parameters of passive absorption (PUWL, Ppara,
and DM/hM ) by tting observed permeabilities for pas-
sively absorbed ompounds with Eq. 2 Pact = 0. Then
these values were frozen and observed permeability val-
ues for atively transported ompounds were tted with
Eq. 2 where Pact was substituted by the proposed model
of ative transport.
B. Estimation the passive absorption model
parameters.
To estimate the parameters of the passive absorption
we tted observed permeability values for drugs, whih to
the best of our knowledge are passively absorbed, with
Figure 3: Model of passive intestinal permeability. Intestinal
permeability of passively absorbed ompounds (lled and hol-
low squares) is plotted against LogD. Solid line is predition
of the model 2, where Pact = 0 cm · s
−1
, Ppara = const. The
parameter values see in the text.
Eq. 2 with no ative transport (Pact = 0). Sine the
approximation ontains only three adjustable parameters
of passive absorption, there was no need in a large data
set. Therefore we seleted passively absorbed ompounds
with Cao-2 permeabilities measured diretly. This was
done beause the observed FA depend on experimental
onditions and may inlude eets of drug instability in
the intestinal uids, intestinal metabolism and so on. On
the ontrary, the data on Cao-2 permeability are free
of those mentioned problems. On the other hand tight
juntions of Cao-2 ell monolayer are signiantly less
permeable [10, 46℄ than in the intestine.
Fig. 3 shows the logarithm of permeability of passively
absorbed drugs (both lled and hollow squares) plotted
against the logarithm of distribution oeient. In aor-
dane with previously proposed model [14℄ the intestinal
permeability of passively absorbed drugs inreases with
inrease in the distribution oeient and saturate at
both low and high ends. The inreasing part reets
growth in membrane permeability with inrease in the
distribution oeient of a drug. The saturation at upper
limit reets diusional limitations imposed by UWLs
for highly lipophili drugs. The saturation at low logD
orresponds to residual permeability through tight jun-
tions. Solid line shows tting of experimental data with
Eq. 2 where Pact = 0, PUWL, Ppara, and DM/hM are
all assumed onstant for all the ompounds. The best t
was ahieved at the following values of the model param-
eters: Ppara = 5.01×10
−8 cm · s−1, PUWL = 2.88×10
−5
cm · s−1, DM/hM = 3.71 × 10
−5 cm · s−1. RMSD were
0.42 log units.
The determined value of Ppara is slightly lower of ex-
perimental estimations ranged from 10−7÷10−6 cm · s−1
5[2, 52℄, while PUWL is in a good agreement with the ob-
served values at slow stirring rate (5 × 10−5 cm · s−1at
25 rpm , [2℄). Using the ommonly aepted value of the
diusion oeient, 10−5 cm2×s−1 [52, 69℄, from Eq. 3
we nd the eetive thikness of UWLs :
hUWL ∼ 3× 10
2 µm
that is in exellent agreement with previously estimated
values between 35 and 800µm, [5, 21℄.
C. The ative absorption model.
Using literature data [18, 31, 39, 46, 63, 64, 73℄ we
seleted 45 ompounds from our database, whih are
reportedly absorbed using ative transport and to the
best of our knowledge are not subjet to drug eux
[24, 39, 46, 64, 66, 73℄. To enrih the data set both the
values of Cao-2 measured diretly and the alulated by
FA permeability values were used. If both FA and Cao-
2 permeability were available for a given ompound, the
value of P alulated from the measured FA was em-
ployed. This is a reasonable approah, sine Cao-2 ells
are known to under express some important drug trans-
porters [16, 41℄, and thus Cao-2 permeability data for
atively transported ompounds is less reliable than FA.
Fig. 4 shows that permeability of the majority of a-
tively absorbed ompounds were higher than predited
by the model of passive absorption in aordane with
existene of an additional omponent of permeability.
Nevertheless there were four outliers, whih permeabil-
ity were substantially below passive permeability urve:
fosinopril, diphenhydramine, lobuavir, and efuroxime
axetil. We will speulate about possible explanations of
this in disussion. For the rest of the ompounds the to-
tal permeability exeeded passive omponent from 0.06
to 3.26 log units and reahed diusion limited rate. This
means that the intensity of ative transport varies in the
wide range and may be limited by drug diusion to the
membrane.
The arrier-mediated absorption (both ative and pas-
sive) an be desribed by Mihaelis-Menten kinetis [48℄:
Pact = Σ
ni/τi
KDi + C
(5)
Jact = Σni/τi
C
KDi + C
(6)
where the summation ours over all (the types of)
transporters; ni is the amount of the i-th transporter
moleules on the unit area of membrane; KDi is the dis-
soiation onstant of the i-th transporter-ligand omplex;
τi is the time, required for the transporter to bind and
arry one moleule aross the membrane; C - ompound
onentration. From Eq. 6 it follows that if C ≪ KDi ,
Figure 4: Intestinal permeability of atively absorbed om-
pounds. Pink points are observed values. Solid line is the
model of passive absorption.
then Jact → 0 (the ompound is passively absorbed). In
the opposite ase C ≫ KDi
Jact = Σni/τi
i.e. a ompound atively absorbed and ative ompo-
nent of a drug ux is independent of drug onentra-
tion and determined only by the amount of the protein-
transporter and time, required for a transporter to arry
a ligand aross membrane. Thus Eq. 6 is similar to a
lassier, with threshold value C, whih selets between
the passive and the ative transport options (possibili-
ties). Therefore it is natural to build a lassier model to
identify proteins that either partiipate in ative trans-
port diretly, or have binding site similar to that of a
transporter.
To identify the proteins related to ative absorption or
with ative site fore eld similar to that of protein trans-
porters we used all drugs that are reported to be atively
absorbed and have permeability not less than predited
by passive model (41 ompound). Besides, 71 passively
absorbed drugs were used. We studied absorption-Kd
relations for these drugs and proteins from our set and
identied a protein that orretly lassied 78% of drugs
between atively and passively transported. Fig. 5 shows
that pratially all ompounds with at least some small
anity for the protein are atively absorbed. Using John
Platt's sequential minimal optimization algorithm for
training a support vetor lassier implemented in Weka
Data Mining Software we build up a lassier model. The
onfusion matrix, as shown on Fig. 5, shows that only 7%
(5 from 66 passively transported ompounds) were mis-
takenly lassied by the model as atively transported.
These outliers may in fat be false-positives, whih an-
ity for the protein was mistakenly alulated as high.
6Figure 5: Relation between anity of a ompound for hu-
man brain hexokinase type I and intestinal absorption meh-
anism of the drug. Blue  atively absorbed ompounds, red
 passively absorbed ompounds. X axis  pKd value for the
hexakinase. Y axis  the number of passively and atively ab-
sorbed ompound. The onfusion matrix shows auray of
predition of ative transport with the help of human brain
hexakinase.
Figure 6: Permeability predition for atively absorbed om-
pounds. Predited permeability for orretly lassied om-
pounds is plotted against experimental values. Both axis are
in logarithmi sale.
Fig. 6 shows permeability predition for ompounds
that were orretly lassied as ative using Eqs. 2 and
5 where ni/τi = 3.2E − 8M ∗ cm
−2s−1 and C = 10E −
30M ∗ cm−3.
Fig. 5 shows that there are a lot of atively trans-
ported ompounds among drugs with zero anity for
the protein. This suggests that there should be other pro-
teins that transport mislassied drugs. The fat that we
failed to nd out them suggest that our protein set misses
some ative site types that are important for intestinal
drug absorption. The onfusion matrix shows that only
51% (21 from 20 atively transported ompounds) were
lassied as suh. However, if we onsider only drugs
with non-zero anity for the protein (4 right bars on the
histogram) 21 from 26 ompounds (81%) were atively
transported, showing that if a ompound has anity for
the protein it is most probably subjet to ative transport
during intestinal absorption. It is neessary to identify
other proteins that lassify drugs as atively transported
ompounds.
In summary, we started from the premise that ative
drug transport an be predited by its anity for some
proteins, whih in fat not obligatory are transporters
but have ative site fore eld similar to that of trans-
porters. Using this approah and John Platt's sequential
minimal optimization algorithm for training a support
vetor lassier we sueeded to identify a protein whih
anity for drugs orrelates with the ative absorption
of these drugs in 81% ases. This protein an be used
for estimation of the drug transport mehanism. The
high perent of atively absorbed ompounds that the
model mistakenly lassies as passively absorbed indi-
ates that there are other proteins that transport these
outliers. The fat that we failed to identify them suggests
that our urrent protein set misses some protein ative
site types that are important for protein absorption and
future steps should be taken to enrih our protein set
with suh ative sites. Nevertheless, identiation of the
rst protein that lassies ompounds between atively
and passively absorbed shows that the proposed onept
for predition of drug absorption is orret.
IV. DISCUSSION
At temps have been made to develop a theoretial
model of oral absorption and intestinal permeability
[14, 50℄. Nevertheless, the models desribed only pas-
sive (trans and paraellular) drug absorption, while a-
tive transport is an important part of it [18℄. In this
paper we presented a novel approah to in silio predi-
tion of intestinal permeability for atively transported
ompounds using binding data to some proteins. The
developed model (2) has the standard passive terms and
inludes an additional ative permeability term. When
the last one is put to zero the model redues to a model of
passive absorption. Fig. 3 shows that the redued (pas-
sive absorption) model fairly good desribes permeability
of passively absorbed ompounds. There were only three
apparent outliers (hollow squares): bupropion, bosentan,
and remikiren. If there were no errors in experimental
data (either permeability or distribution oeient) we
assumed that these ompounds were subjeted to either
eux or intestinal metabolism. Fig 4 shows that the
majority of atively transported ompounds were above
passive absorption urve, indiating existene of an ad-
ditional omponent of permeability, besides passive one.
Nevertheless there were also outliers, whih permeabil-
ity were substantially below passive permeability urve:
fosinopril, diphenhydramine, lobuavir, and efuroxime
axetil. This an be due to inauray in experimental
data, or due to eux of the drug from the ell or due
7intestinal metabolism, that does not disovered yet.
The ative absorption term in our model is determined
by Mihaelis-Menten kinetis [48℄. If a ompound has
high anity for important for ative transport proteins
it is predited to be atively absorbed otherwise the a-
tive omponent is low and the ompound is largely pas-
sively absorbed. The anity data an be estimated using
moleular doking software. However, there are prati-
ally no resolved strutures of transporters, nevertheless
there may be proteins with similar fore eld in the a-
tive site that are solved and an be used for doking.
Indeed, we identied the rst suh protein . It is hu-
man brain hexokinase. From 26 ompounds with high
alulated anity for the protein 21 (81%) were atively
transported. It is not a transporter, in fat, however the
orrelation suggests that that there is a transporter with
similar ative site fore eld. Thus the transporter an be
represented by this protein. Fig. 6shows that the model
using anitiesfor this protein gives reasonably good pre-
ditions for orretly lassied ompounds.
Further eorts should be made to identify the rest of
the ative site types important for drug absorption in the
intestine. Fig. 5 shows that there are a lot of atively
transported ompounds among drugs with zero anity
for the protein. This suggests that there should be other
ative site types relevant to drug ative transport. The
fat that we failed to identify them suggests that our pro-
tein set misses some ative site types that are important
for intestinal drug absorption. Thus the work should be
ontinued in this dire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